1300P A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
Lin Wu, Bolin Chen, W. Yao, X. Li, Z. Xiao, H. Liu, Yi Kong, Lina Liu, Yan Xu, Q. Wang, J. Li, Fang Xu, Long Xu, K. Li, Weifeng Song, B. Li, Z.M. Wang, Yu Xia
Topics & Concepts
MedicineCancer researchCTLA-4ChemotherapyAngiogenesisLung cancerOncologyImmune checkpointAntibodyTyrosine kinaseImmunotherapyInternal medicineVascular endothelial growth factorPharmacologyCancerImmunologyImmune systemReceptorT cellVEGF receptorsLung Cancer Research StudiesPeptidase Inhibition and AnalysisCancer Immunotherapy and Biomarkers